Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klein, E. A.
Right arrow Articles by Thompson, I. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Klein, E. A.
Right arrow Articles by Thompson, I. M.

Current Status of Chemoprevention of Prostate Cancer

Eric A. Klein, MD, and Ian M. Thompson, MD

From the Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH (Dr Klein), and the Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX (Dr Thompson)

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to Eric A. Klein, MD, Interim Chair, Glickman Urological and Kidney Institute, Professor of Surgery, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Dept of Urology, Desk A100, 9500 Euclid Ave, Cleveland OH 44195; e-mail: Kleine{at}ccf.org

Overview: Prostate cancer is an attractive target for primary chemoprevention strategies because of its molecular pathogenesis, incidence, prevalence, treatment-related morbidity and mortality. In the last several years, many large scale primary and secondary prevention trials have been initiated and completed, and the results of several more are anticipated in 2009. A brief review of the rationale, design, and results (where available) is provided.